Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Study of HDM1005 at Different Injection Sites
NCT07828197Phase 1Active, not recruiting
- Sponsor
- Huadong Medicine
- Start
- Sep 2026
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of poterepatide in obesity (3 cohorts), sponsored by Huadong Medicine. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration and 1 more. Started Sep 2026; status: active, not recruiting.
02
Drugs
poterepatide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07828197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07828197.